Oppenheimer Maintains Outperform on Tvardi Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk 21 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Jay Olson maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform and lowers the price target from $10 to $9.
Oppenheimer analyst Jay Olson maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform and lowers the price target from $10 to $9.
